- Home
- TRU vs INSM Comparison
TRU vs INSM Comparison
Compare TRU & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRU
- INSM
- Stock Information
- Founded
- TRU 1968
- INSM 1988
- Country
- TRU United States
- INSM United States
- Employees
- TRU N/A
- INSM N/A
- Industry
- TRU Finance: Consumer Services
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- TRU Finance
- INSM Health Care
- Exchange
- TRU Nasdaq
- INSM Nasdaq
- Market Cap
- TRU 17.5B
- INSM 19.1B
- IPO Year
- TRU 2015
- INSM 2000
- Fundamental
- Price
- TRU $99.23
- INSM $103.95
- Analyst Decision
- TRU Buy
- INSM Strong Buy
- Analyst Count
- TRU 12
- INSM 17
- Target Price
- TRU $115.36
- INSM $109.20
- AVG Volume (30 Days)
- TRU 2.5M
- INSM 4.1M
- Earning Date
- TRU 07-24-2025
- INSM 08-07-2025
- Dividend Yield
- TRU 0.47%
- INSM N/A
- EPS Growth
- TRU N/A
- INSM N/A
- EPS
- TRU 1.99
- INSM N/A
- Revenue
- TRU $4,357,300,000.00
- INSM $381,030,000.00
- Revenue This Year
- TRU $6.55
- INSM $28.17
- Revenue Next Year
- TRU $8.95
- INSM $120.09
- P/E Ratio
- TRU $49.33
- INSM N/A
- Revenue Growth
- TRU 9.34
- INSM 20.77
- 52 Week Low
- TRU $66.38
- INSM $60.40
- 52 Week High
- TRU $113.17
- INSM $106.83
- Technical
- Relative Strength Index (RSI)
- TRU 69.83
- INSM 66.75
- Support Level
- TRU $90.36
- INSM $101.55
- Resistance Level
- TRU $94.73
- INSM $103.74
- Average True Range (ATR)
- TRU 2.77
- INSM 2.58
- MACD
- TRU 0.53
- INSM -0.49
- Stochastic Oscillator
- TRU 98.91
- INSM 86.11
About TRU TransUnion
TransUnion is one of the three leading credit bureaus in the United States, providing the consumer information that is the basis for granting credit. The company also provides fraud detection, marketing, and analytical services. TransUnion operates in over 30 countries, and about a quarter of its revenue comes from international markets.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.